文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

急诊科静脉与肌内注射奥氮平患者的前瞻性观察研究

A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department.
PubMed 文献 · Ann Emerg Med · 2016-11-04
一句话结论急诊科前瞻性观察显示,在适当监测下,静脉与肌内注射奥氮平均较安全,静脉组呼吸抑制发生率3.7%、肌内组2.0%。

该前瞻性观察研究在一家城市I级创伤中心急诊科纳入784例接受胃肠外奥氮平的患者,其中静脉组295例、肌内组489例。主要终点呼吸抑制发生率静脉组为3.7%(95%CI 1.6%至5.9%),肌内组为2.0%(95%CI 0.8%至3.3%);需插管者7例(静脉组2例、肌内组5例)。非呼吸系统并发症静脉组6例(2.0%,95%CI 0.4%至3.6%)、肌内组2例(0.4%,95%CI 0%至0.96%),心律失常仅2次心动过缓且仅需支持治疗。作者认为,在适当监测下,肌内与静脉注射奥氮平用于急诊多种适应证均安全。

要点

  • 静脉注射奥氮平295例中呼吸抑制11例(3.7%,95%CI 1.6%至5.9%),肌内注射489例中10例(2.0%,95%CI 0.8%至3.3%)。
  • 全组7例需插管,静脉组2例、肌内组5例。
  • 非呼吸系统并发症静脉组6/295(2.0%,95%CI 0.4%至3.6%),肌内组2/489(0.4%,95%CI 0%至0.96%)。
  • 心律失常仅2次心动过缓,仅需支持治疗。
  • 作者认为,在适当监测下,静脉与肌内注射奥氮平用于急诊多种适应证均安全。

适用人群与场景

  • 就诊于城市I级创伤中心急诊科、接受胃肠外奥氮平治疗多种适应证的患者。

研究设计与关键结果

  • 前瞻性观察研究,最终分析纳入784例患者,其中静脉注射奥氮平295例、肌内注射奥氮平489例。
  • 主要终点呼吸抑制:静脉组11/295(3.7%,95%CI 1.6%至5.9%),肌内组10/489(2.0%,95%CI 0.8%至3.3%)。
  • 需插管者共7例,静脉组2例、肌内组5例。
  • 非呼吸系统并发症:静脉组6/295(2.0%,95%CI 0.4%至3.6%),肌内组2/489(0.4%,95%CI 0%至0.96%)。
  • 心律失常仅2次心动过缓,仅需支持治疗。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在适当监测下,静脉与肌内注射奥氮平用于急诊多种适应证均安全。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Parenteral olanzapine is an emerging therapy for a variety of conditions in the emergency department (ED). Intramuscular administration is standard; however, intravenous administration has been proposed as a safe alternative route. We investigate the safety and efficacy of both intramuscular and intravenous olanzapine in the ED when used for a variety of indications.

METHODS: This was a prospective observational study of patients presenting to an urban Level I trauma center ED. Trained research associates screened the ED for patients receiving parenteral olanzapine. The primary outcome of the study was incidence of respiratory depression measured with standard markers. Secondary outcomes included use of additional doses or sedatives, corrected QT interval (QTc) data, time to nadir sedation, adverse events, and physician assessment of efficacy.

RESULTS: There were 784 patients included in the final analysis. Intravenous olanzapine was administered to 295 patients; 489 received intramuscular olanzapine. Respiratory depression occurred in 11 of 295 patients (3.7%; 95% confidence interval [CI] 1.6% to 5.9%) receiving intravenous olanzapine and 10 of 489 (2.0%; 95% CI 0.8% to 3.3%) receiving intramuscular olanzapine. Seven patients required intubation, 2 in the intravenous group and 5 in the intramuscular group. Nonrespiratory complications occurred in 8 patients, 6 of 295 (2.0%; 95% CI 0.4% to 3.6%) in the intravenous group and 2 of 489 (0.4%; 95% CI 0% to 0.96%) in the intramuscular group. Dysrhythmias were isolated to 2 episodes of bradycardia requiring only supportive care.

CONCLUSION: These data suggest that, with proper monitoring, administration of olanzapine, both intramuscular and intravenous, is safe for several indications in the ED.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Cole JB, Moore JC, Dolan BJ, et al. A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department. Ann Emerg Med. 2016. PMID: 27823873. doi:10.1016/j.annemergmed.2016.08.008

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。